TiCARos
June 18, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
153A
TiCARos is a clinical-stage South Korean biotech company developing next-generation CAR-T and CAR-NK cell therapies to overcome the limitations of current immunotherapies. We leverage two proprietary platforms: CLIP (CAR Library Integrative Platform) for high-throughput CAR optimization, and Converter technology (CTC28), which rewires inhibitory immune signals into stimulatory ones to boost anti-tumor activity in solid and hematologic cancers. Our lead asset, TC011, has demonstrated 100% complete response in both low- and mid-dose cohorts in a Phase 1 trial. TiCARos operates its own GMP manufacturing using the Prodigy system and collaborates globally with academic and industry partners. We are a proud JLABS portfolio company, advancing cell therapies with strong translational potential and a mission to cure intractable cancers.
Company HQ City:
Seoul City
Company HQ State:
Seoul City (State)
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
TC011: Hematological malignancies (lymphoma) targeting anti-CD19 CLIP-technology applied CAR-T
TC071: Solid tumor targeting anti-MUC-1 CLIP-applied CAR-T
TC031: Solid tumor targeting anti-B7H3 Converter-applied CAR-T
CEO
Jaewon Lee, Prof.Choi Kyungho, Prof. Choi Enyoung (CEO, CTO, CSO)
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Three
When you expect your next catalyst update?
Our next major catalyst is the upcoming clinical update from our Phase 1 trial of TC011, our lead CLIP-CAR-T asset targeting relapsed/refractory B-cell lymphoma. Following 100% complete response rates in the low- and mid-dose cohorts, we anticipate presenting data from the high-dose cohort in the near term. This will further validate the safety, efficacy, and scalability of our platform.
In parallel, preclinical data from our TF-CLIP-CAR-NK program, developed in collaboration with Cartherics, is expected to be disclosed later this year. These results will provide proof-of-concept for our CLIP technology in solid tumors and in allogeneic NK formats.
We also plan to announce new strategic partnerships and licensing discussions as we engage with global biopharma partners interested in co-developing or accessing our modular CAR platforms.
What is your next catalyst (value inflection) update?
Q3, 2025
Website
www.ticaros.com/en
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}